Flat Peach SUBLOR and SUBLIM and Flat Nectarine PERLA Series

Flat peach and flat nectarine (Prunus persica L. Batsch.) production in Spain started from local cultivars at marginal sites, mainly in the Ebro Valley and Murcia regions. At the end of the 1990s, the introduction of improved cultivars from France and Italy, with more red skin color coverage and better regular shape, fruit size, and stylar cavity closure, together with superior handling and transport conditions led the Spanish peach sector to develop this fruit type on a commercial scale. Currently, Spain is the largest European producer and exporter of flat peach and nectarine, offering a wide range of cultivars covering the producing period from May to September. In 2020, a total of 10.200 ha for flat peach and 481 ha for flat nectarine together produced 263.651 t (20% of the total peach production) (MAPAMA, 2022). To guarantee adaptation to local growing conditions (Font i Forcada et al., 2021a), several national breeding programs started to develop new flat peach and flat nectarine cultivars. One of these breeding programs is the ASF-IRTA breeding program, which is located at Gimenells (Lleida) in the Ebro Valley (northeastern Spain), which is a major region of peach production in Spain (Batlle et al., 2012; Cantín et al., 2017). It was started in 2004, with the objective of developing new cultivars adapted to chilling between 1000 and 1500 chill units or between 42 and 75 chill portions and warm conditions similar to the Mediterranean area (32 °C mean daily summer temperature and 300–400 mm of annual rainfall). It aimed to produce high-quality fruits, both at harvest and after cold storage, with the ultimate goal of satisfying consumers (Font i Forcada et al., 2021a, 2021b). As a result of this collaborative effort, the ASF-IRTA scion peach breeding program has already released the SUBLOR (one flat yellow-fleshed peach), SUBLIM (six flat white-fleshed peach), and PERLA (two flat white-fleshed nectarine) series. These nine new flat peach and nectarine cultivars produce highly attractive yellow-fleshed or white-fleshed fruits with high coverage of red skin, a balanced or acid flavor, sweet taste, and good flesh firmness. The harvesting calendar of these series will be progressively completed with new future releases.info:eu-repo/semantics/publishedVersio

MAGNA and BLANQ Series: Two Yellow-fleshed and Three White-fleshed Nectarines

The continuous release of new nectarine [Prunus persica (L.) Batsch] cultivars by breeders from around the world, together with consistent improvements in orchard management strategies by growers, commercial interest in the production of fruit fresh consumption, and the introduction of new cultivars from Spanish scion nectarine breeding programs have positioned Spain as the preeminent worldwide nectarine exporter and currently the largest European producer [Ministry of Agriculture, Food and Environment (MAPAMA), 2021]. In Spain, the main nectarine-producing area is the Ebro Valley that accounts for more than 60% of the total Spanish peach and nectarine production (MAPAMA, 2021).info:eu-repo/semantics/publishedVersio

TERRAM and LUX series : Four yellow-fleshed and three white-fleshed peaches

Altres ajuts: CERCA Programme/Generalitat de Cataluny

MAGNA and BLANQ series : Two yellow-fleshed and three white-fleshed nectarines

Altres ajuts: CERCA Programme/Generalitat de Cataluny

Protocol for validation of the Global Scales for Early Development (GSED) for children under 3 years of age in seven countries.

IntroductionChildren's early development is affected by caregiving experiences, with lifelong health and well-being implications. Governments and civil societies need population-based measures to monitor children's early development and ensure that children receive the care needed to thrive. To this end, the WHO developed the Global Scales for Early Development (GSED) to measure children's early development up to 3 years of age. The GSED includes three measures for population and programmatic level measurement: (1) short form (SF) (caregiver report), (2) long form (LF) (direct administration) and (3) psychosocial form (PF) (caregiver report). The primary aim of this protocol is to validate the GSED SF and LF. Secondary aims are to create preliminary reference scores for the GSED SF and LF, validate an adaptive testing algorithm and assess the feasibility and preliminary validity of the GSED PF.Methods and analysisWe will conduct the validation in seven countries (Bangladesh, Brazil, Côte d'Ivoire, Pakistan, The Netherlands, People's Republic of China, United Republic of Tanzania), varying in geography, language, culture and income through a 1-year prospective design, combining cross-sectional and longitudinal methods with 1248 children per site, stratified by age and sex. The GSED generates an innovative common metric (Developmental Score: D-score) using the Rasch model and a Development for Age Z-score (DAZ). We will evaluate six psychometric properties of the GSED SF and LF: concurrent validity, predictive validity at 6 months, convergent and discriminant validity, and test-retest and inter-rater reliability. We will evaluate measurement invariance by comparing differential item functioning and differential test functioning across sites.Ethics and disseminationThis study has received ethical approval from the WHO (protocol GSED validation 004583 20.04.2020) and approval in each site. Study results will be disseminated through webinars and publications from WHO, international organisations, academic journals and conference proceedings.Registration detailsOpen Science Framework https://osf.io/ on 19 November 2021 (DOI 10.17605/OSF.IO/KX5T7; identifier: osf-registrations-kx5t7-v1)

Almanach des orphéons et des sociétés instrumentales... / par M. M. Camille de Vos, Ch. Coligny, Jules-Janin, Arsène Houssaye, Emile Deschamps, Roger de Beauvoir, Em. de la Bedollière, Eugène d'Auriac, A. de Pontécoulant, Léon Escudier, Léon Gatayes, Lomon, H. Vié, Firmin Maillard, Anders, Joannis Guigard, Jules Mahias, de Lyden, Alexis Faure, Eliacim Jourdain, Benjamin Gastineau, Nozahies, etc. ; sous la direction de J. F. Vaudin,...

Variante(s) de titre : Almanach des orphéonsPériodicité : Annue

Almanach des orphéons et des sociétés instrumentales... / par M. M. Camille de Vos, Ch. Coligny, Jules-Janin, Arsène Houssaye, Emile Deschamps, Roger de Beauvoir, Em. de la Bedollière, Eugène d'Auriac, A. de Pontécoulant, Léon Escudier, Léon Gatayes, Lomon, H. Vié, Firmin Maillard, Anders, Joannis Guigard, Jules Mahias, de Lyden, Alexis Faure, Eliacim Jourdain, Benjamin Gastineau, Nozahies, etc. ; sous la direction de J. F. Vaudin,...

18631863 (A1)

Almanach des orphéons et des sociétés instrumentales... / par M. M. Camille de Vos, Ch. Coligny, Jules-Janin, Arsène Houssaye, Emile Deschamps, Roger de Beauvoir, Em. de la Bedollière, Eugène d'Auriac, A. de Pontécoulant, Léon Escudier, Léon Gatayes, Lomon, H. Vié, Firmin Maillard, Anders, Joannis Guigard, Jules Mahias, de Lyden, Alexis Faure, Eliacim Jourdain, Benjamin Gastineau, Nozahies, etc. ; sous la direction de J. F. Vaudin,...

18641864 (A2)

Characterisation of a high-risk profile for maternal thrombotic and severe haemorrhagic complications in pregnant women with antiphospholipid syndrome in France (GR2): a multicentre, prospective, observational study

International audienceBackgroundProspective data about the risks of thrombotic and severe haemorrhagic complications during pregnancy and post partum are unavailable for women with antiphospholipid syndrome. We aimed to assess thrombotic and haemorrhagic events in a prospective cohort of pregnant women with antiphospholipid syndrome.MethodsThis multicentre, prospective, observational study was done at 76 centres in France. To be eligible for this study, women had to have diagnosis of antiphospholipid syndrome; have conceived before April 17, 2020; have an ongoing pregnancy that had reached 12 weeks of gestation; and be included in the study before 18 weeks of gestation. Exclusion criteria were active systemic lupus erythematosus nephropathy, or a multifetal pregnancy. Severe haemorrhage was defined as the need for red blood cell transfusion or maternal intensive care unit admission because of bleeding or invasive procedures, defined as interventional radiology or surgery, to control bleeding. The GR2 study is registered with ClinicalTrials.gov, NCT02450396.FindingsBetween May 26, 2014, and April 17, 2020, 168 pregnancies in 27 centres met the inclusion criteria for the study. 89 (53%) of 168 women had a history of thrombosis. The median term at inclusion was 8 weeks gestation. 16 (10%) of 168 women (95%CI 5–15) had a thrombotic (six [4%] women; 95% CI 1–8) or severe haemorrhagic event (12 [7%] women; 95% CI 4–12). There were no deaths during the study. The main risk factors for thrombotic events were lupus anticoagulant positivity at inclusion (six [100%] of six women with thrombosis vs 78 [51%] of 152 of those with no thrombosis; p=0·030) and placental insufficiency (four [67%] of six women vs 28 [17%] of 162 women; p=0·013). The main risk factors for severe haemorrhagic events were pre-existing maternal hypertension (four [33%] of 12 women vs 11 [7%] of 156 women; p=0·014), lupus anticoagulant positivity at inclusion (12 [100%] of 12 women vs 72 [49%] of 146 women; p<0·0001) and during antiphospholipid history (12 [100%] of 12 women vs 104 [67%] of 156 women; p=0·019), triple antiphospholipid antibody positivity (eight [67%] of 12 women vs 36 [24%] of 147 women; p=0·0040), placental insufficiency (five [42%] of 12 women vs 27 [17%] of 156 women; p=0·038), and preterm delivery at 34 weeks or earlier (five [45%] of 11 women vs 12 [8%] of 145 women; p=0·0030).InterpretationDespite treatment adhering to international recommendations, a proportion of women with antiphospholipid syndrome developed a thrombotic or severe haemorrhagic complication related to pregnancy, most frequently in the post-partum period. Lupus anticoagulant and placental insufficiency were risk factors for these life-threatening complications. These complications are difficult to prevent, but knowledge of the antenatal characteristics associated with them should increase awareness and help physicians manage these high-risk pregnancies

Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients

International audienceObjectives: There is little known about the impact of SARS-CoV-2 on patients with inflammatory rheumatic and musculoskeletal diseases (iRMD). We examined epidemiological characteristics associated with severe disease, then with death. We also compared mortality between patients hospitalised for COVID-19 with and without iRMD.Methods: Individuals with suspected iRMD-COVID-19 were included in this French cohort. Logistic regression models adjusted for age and sex were used to estimate adjusted ORs and 95% CIs of severe COVID-19. The most significant clinically relevant factors were analysed by multivariable penalised logistic regression models, using a forward selection method. The death rate of hospitalised patients with iRMD-COVID-19 (moderate-severe) was compared with a subset of patients with non-iRMD-COVID-19 from a French hospital matched for age, sex, and comorbidities.Results: Of 694 adults, 438 (63%) developed mild (not hospitalised), 169 (24%) moderate (hospitalised out of the intensive care unit (ICU) and 87 (13%) severe (patients in ICU/deceased) disease. In multivariable imputed analyses, the variables associated with severe infection were age (OR=1.08, 95% CI: 1.05-1.10), female gender (OR=0.45, 95% CI: 0.25-0.80), body mass index (OR=1.07, 95% CI: 1.02-1.12), hypertension (OR=1.86, 95% CI: 1.01-3.42), and use of corticosteroids (OR=1.97, 95% CI: 1.09-3.54), mycophenolate mofetil (OR=6.6, 95% CI: 1.47-29.62) and rituximab (OR=4.21, 95% CI: 1.61-10.98). Fifty-eight patients died (8% (total) and 23% (hospitalised)). Compared with 175 matched hospitalised patients with non-iRMD-COVID-19, the OR of mortality associated with hospitalised patients with iRMD-COVID-19 was 1.45 (95% CI: 0.87-2.42) (n=175 each group).Conclusions: In the French RMD COVID-19 cohort, as already identified in the general population, older age, male gender, obesity, and hypertension were found to be associated with severe COVID-19. Patients with iRMD on corticosteroids, but not methotrexate, or tumour necrosis factor alpha and interleukin-6 inhibitors, should be considered as more likely to develop severe COVID-19. Unlike common comorbidities such as obesity, and cardiovascular or lung diseases, the risk of death is not significantly increased in patients with iRMD